Long-Term Systemic Expression of a Novel PD-1 Blocking Nanobody from an AAV Vector Provides Antitumor Activity without Toxicity

Long-Term Systemic Expression of a Novel PD-1 Blocking Nanobody from an AAV Vector Provides Antitumor Activity without Toxicity

Immune checkpoint blockade using monoclonal antibodies (mAbs) able to block programmed death-1 (PD-1)/PD-L1 axis represents a promising treatment for cancer. However, it requires repetitive systemic administration of high mAbs doses, often leading to adverse effects. We generated a novel nanobody ag...

Full description

Bibliographic Details
Main Authors: Noelia Silva-Pilipich, Eva Martisova, María Cristina Ballesteros-Briones, Sandra Hervas-Stubbs, Noelia Casares, Gualberto González-Sapienza, Cristian Smerdou, Lucia Vanrell
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Biomedicines
Subjects:
nanobody
VHH
PD-1
PD-L1
AAV vector
cancer
Online Access:https://www.mdpi.com/2227-9059/8/12/562

Similar Items

Similar Items